16315-16-5

Usage

InChI:InChI=1/C10H14N2O/c1-6-9-7(12-11-6)4-10(2,3)5-8(9)13/h4-5H2,1-3H3,(H,11,12)

Upstream product

• 37513-99-8 2-acetyldimedone 
• 177211-18-6 (E)-(3,6,6-trimethyl-6,7-dihydro-1,2-benzisoxazol-4(5H)-one oxime) 
• 1755-15-3 2-acetyldimedone 
• 53173-69-6 3,6,6-trimethyl-6,7-dihydro-1,2-benzisoxazol-4(5H)-one 
• 3471-13-4 dimedone 
• 126-81-8 dimedone 

Downstream Products

• 1073973-95-1 2-fluoro-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazole-1-yl)benzonitrile 
• 1432509-42-6 methyl 4-((3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydroindazol-1-yl)methyl)benzoate 
• 1432508-29-6 N-hydroxy-4-((3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydroindazol-1-yl)methyl)benzamide 
• 1433958-18-9 tert-butyl 4-(((2-carbamoyl-5-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)phenyl)amino)methyl)piperidine-1-carboxylate 
• 1433958-17-8 tert-butyl 4-(((2-cyano-5-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)phenyl)amino)methyl)piperidine-1-carboxylate 
• 1392213-68-1 2-bromo-5-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydroindazol-2-yl)benzonitrile 
• 1392213-66-9 2-bromo-5-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydroindazol-1-yl)-benzonitrile 
• 1392213-71-6 C₃₁H₃₃N₇O 
• 1392213-69-2 C₃₁H₃₃N₇O 
• 1392213-65-8 2-((2-[bis(pyridin-2-ylmethyl)amino]ethyl)amino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydroindazol-2-yl)benzamide 
• 1392213-64-7 2-((2-[bis(pyridin-2-ylmethyl)amino]ethyl)amino)-5-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydroindazol-2-yl)benzamide 
• 1392213-63-6 2-((2-[bis(pyridin-2-ylmethyl)amino]ethyl)amino)-5-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydroindazol-1-yl)benzamide 
• 1392213-67-0 2-((2-[bis(pyridin-2-ylmethyl)amino]ethyl)amino)-5-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydroindazol-1-yl)benzonitrile 
• 908111-29-5 2-bromo-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)benzonitrile 

Relevant academic research and scientific papers

Tetrahydroindazole inhibitors of CDK2/cyclin complexes

Over 50 tetrahydroindazoles were synthesized after 7-bromo-3,6,6-trimethyl-1-(pyridin-2-yl)-5,6,7,7a-tetrahydro-1H-indazol-4(3aH)-one (3) was identified as a hit compound in a high throughput screen for inhibition of CDK2 in complex with cyclin A. The activity of the most promising analogues was evaluated by inhibition of CDK2 enzyme complexes with various cyclins. Analogues 53 and 59 showed 3-fold better binding affinity for CDK2 and 2- to 10-fold improved inhibitory activity against CDK2/cyclin A1, E, and O compared to screening hit 3. The data from the enzyme and binding assays indicate that the binding of the analogues to a CDK2/cyclin complex is favored over binding to free CDK2. Computational analysis was used to predict a potential binding site at the CDK2/cyclin E1 interface.

A 2 - (grantane - 3 - amino) - 4 - tetrahydroindazole substituted benzamide compound and use thereof

The invention belongs to the field of medicines, and particularly relates to a 2-(granatane3-amino)-4-tetrahydronaphthalene indazole-substituted benzamide compound and an application thereof. The 2-(granatane3-amino)-4-tetrahydronaphthalene indazole-substituted benzamide compound has a structure shown in a formula I in the specification, wherein R1 is a hydrogen group or an alkyl group and the like; R2 is a hydrogen group, an alkyl group or a hetero-atom-substituted alkyl group and the like. The compound is obtained by substituting the second site of 4-tetrahydronaphthalene indazole-substituted benzamide with granatane-3-amino. Growth of a plurality of tumor cells can be inhibited; the tumor cells can be induced to move towards an apoptosis channel; and the 2-(granatane3-amino)-4-tetrahydronaphthalene indazole-substituted benzamide compound has potential application value in the fields such as tumor treatment and auxiliary treatment.

HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF

The present invention relates to a novel hydroxamate derivatives, more specifically, to novel hydroxamate derivatives having inhibitory activity against Histone Deacetylase (HDAC), isomers thereof, pharmaceutically acceptable salts thereof, hydrates or solvates thereof, use for preparing pharmaceutical compositions, pharmaceutical compositions comprising the same, treatment method using said composition, and a preparing method of novel hydroxamate derivatives. The novel selective hydroxamate derivatives having inhibitory activity against Histone Deacetylase (HDAC) compositions can be used for treatment of inflammatory disease, rheumatoid arthritis, or degenerative disease.

Discovery, structure-activity relationship studies, and anti-nociceptive effects of 1-phenyl-3,6,6-trimethyl-1,5,6,7-tetrahydro-4H-indazol-4-one as novel opioid receptor agonists

The μ-opioid receptor (MOR) is the major opioid receptor targeted by most analgesics in clinical use. However, the use of all known MOR agonists is associated with severe adverse effects. We reported that the 1-phenyl-3,6,6-trimethyl-1,5,6,7-tetrahydro-4H-indazol-4-ones are novel opioid receptor agonists. Subsequent structural modification resulted in the potent MOR/KOR (κ-opioid receptor) agonists 19, 20, and 21. Testing the analgesic effect of these in WT B6 mice (tail-flick test) gave ED50 values of 8.4, 10.9, and 26.6 mg/kg, respectively. The 1-phenyl-3,6,6-trimethyl-1,5,6,7- tetrahydro-4H-indazol-4-one core could be addressed in 1 or 2 synthetic steps with moderate to high percent of yield. In the adenylyl cyclase assay, compound 19 displayed a MOR/KOR agonist profile, with IC50 values of 0.73 and 0.41 μM, respectively. Current results suggest that compound 19 is a promising lead to go further development and in vitro/in vivo adverse effects studies.

HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF

The present invention relates to a novel hydroxamate derivatives, more specifically, to novel hydroxamate derivatives having inhibitory activity against Histone Deacetylase (HDAC), isomers thereof, pharmaceutically acceptable salts thereof, hydrates or solvates thereof, use for preparing pharmaceutical compositions, pharmaceutical compositions comprising the same, treatment method using said composition, and a preparing method of novel hydroxamate derivatives. The novel selective hydroxamate derivatives having inhibitory activity against Histone Deacetylase (HDAC) compositions can be used for treatment of inflammatory disease, rheumatoid arthritis, or degenerative disease.

Synthesis and structural study of tetrahydroindazolones

Multinuclear magnetic resonance spectroscopy allowed us to characterize four 1(2),5,6,7-tetrahydro-4H-indazol-4-one derivatives (1-4) and establish the most stable tautomer in each case. The crystal structure of 6,6-dimethyl-1(2),5,6,7-tetrahydro-4H-indaz

4,5,6,7-tetrahydroindazole derivatives as antitumor agents

Compounds which are 4,5,6,7-tetrahydroindazole derivative formula (1), wherein the dotted line (x) represents a single or double bond; n is 0 or 1; R1, R2 and R3 have the meanings reported in the description; Ra, R′a, Rb, R′b, Rc, R′c have the meanings reported in the description, also comprising that Ra and Rb together and/or Ra and Rc together form a N-alkylpiperydinyl ring with 1 to 6 carbon atoms in the alkyl chain or a phenyl ring; or pharmaceutically acceptable salts thereof, are useful for treating cell proliferative disorders and Alzheimer's disease.

Molybdenum hexacarbonyl promoted ring-opening of hydroxyimino isoxazoles: Unexpected pyrazole formation

Fused isoxazoles underwent reductive ring-opening in the presence of molybdenum hexacarbonyl to give the corresponding β-disubstituted compounds. 3,6,6-Trimethyl-6,7-dihydro-1,2-benzisoxazol-4(5H)-one oxime underwent reductive ring-opening in the presence of molybdenum hexacarbonyl to give 3,6,6-trimethyl-6,7-dihydro-1H-indazol-4(5H)-one. A mechanism is proposed.

A Novel Lysine-protecting Procedure for Continuous Flow Solid Phase Synthesis of Branched Peptides

A new amine protecting group which can be used orthogonally with both Fmoc and Boc protection is reported; by employing lysine protected appropriately as the branching motif, a 34 residue di-epitopic peptide has been constructed by continuous flow solid phase peptide synthesis.